CFO and Chief Business Officer · Latigo Biotherapeutics, Inc. · Latigo Biotherapeutics, Inc. — Employee Stock Option (right to buy)
Side
A
Value
—
Shares
175.0K
Price
—
Executed
Nov 15, 2026
Disclosed
Nov 18, 2026
Disclosure timeline3 days from execution to publication · legal deadline 2 business days
Nov 15 executedNov 18, 2026 disclosed
LTGO · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing+6 / 15
Disclosed 3 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Latigo Biotherapeutics, Inc. — Employee Stock Option (right to buy)
Ticker
LTGO
Shares
175.0K
Price per share
$0
Execution date (reported)
Nov 15, 2026
Owned after transaction
175.0K shares
Days from execution to publication
3
What this establishes
Krishnamohan Neha filed this Form 4 reporting a grant or award of LTGO on Nov 15, 2026. It became public on Nov 18, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
CFO and Chief Business Officer
Krishnamohan Nehacik:0001866171
Issuer
Latigo Biotherapeutics, Inc.cik:0002056611
Revision history · 0
No field has changed since this record was first ingested.